发明授权
US08323653B2 Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
有权
人源化抗CD19抗体及其在治疗肿瘤，移植和自身免疫疾病中的应用
- 专利标题： Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
- 专利标题（中）： 人源化抗CD19抗体及其在治疗肿瘤，移植和自身免疫疾病中的应用
-
申请号： US11852106申请日： 2007-09-07
-
公开(公告)号： US08323653B2公开(公告)日： 2012-12-04
- 发明人: Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
- 申请人： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
- 申请人地址： US MD Gaithersburg
- 专利权人： MedImmune, LLC
- 当前专利权人： MedImmune, LLC
- 当前专利权人地址： US MD Gaithersburg
- 代理机构： MedImmune, LLC
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; C07K16/30 ; A61K39/395
摘要：
The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.